Adjustment of dosing of antimicrobial agents for bodyweight in adults

The Lancet

Volumn 375, Issue 9710, 2010, Pages 248-251

  Falagas, Matthew E ^a,b,c   Karageorgopoulos, Drosos E ^a  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; COTRIMOXAZOLE; FOSFOMYCIN; LINCOSAMIDE DERIVATIVE; MACROLIDE; MONOBACTAM; PENICILLIN DERIVATIVE; POLYMYXIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE;

ADULT; ADULT DISEASE; ARTICLE; BODY SIZE; BODY WEIGHT; DOSE CALCULATION; HUMAN; INFECTION; PRESCRIPTION; PRIORITY JOURNAL;

EID: 73949117180     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60743-1     Document Type: Note

References (30)

1. Meisel C., Roots I., Cascorbi I., Brinkmann U., and Brockmoller J. How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport. Clin Chem Lab Med 38 (2000) 869-876
2. Hall II R.G., Payne K.D., Bain A.M., et al. Multicenter evaluation of vancomycin dosing: emphasis on obesity. Am J Med 121 (2008) 515-518
3. Janmahasatian S., Duffull S.B., Ash S., Ward L.C., Byrne N.M., and Green B. Quantification of lean bodyweight. Clin Pharmacokinet 44 (2005) 1051-1065
4. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 suppl 2 (2007) S27-S72
5. Ogden C.L., Carroll M.D., Curtin L.R., McDowell M.A., Tabak C.J., and Flegal K.M. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295 (2006) 1549-1555
6. Berghöfer A., Pischon T., Reinhold T., Apovian C.M., Sharma A.M., and Willich S.N. Obesity prevalence from a European perspective: a systematic review. BMC Public Health 8 (2008) 200
7. Peck C.C., and Cross J.T. "Getting the dose right": facts, a blueprint, and encouragements. Clin Pharmacol Ther 82 (2007) 12-14
8. Pai M.P., and Bearden D.T. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 27 (2007) 1081-1091
9. Erstad B.L. Which weight for weight-based dosage regimens in obese patients?. Am J Health Syst Pharm 59 (2002) 2105-2110
10. Pearson T.C., Guthrie D.L., Simpson J., et al. Interpretation of measured red cell mass and plasma volume in adults: expert panel on radionuclides of the International Council for Standardization in Haematology. Br J Haematol 89 (1995) 748-756
11. Blouin R.A., and Warren G.W. Pharmacokinetic considerations in obesity. J Pharm Sci 88 (1999) 1-7
12. Benedek I.H., Blouin R.A., and McNamara P.J. Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects. Br J Clin Pharmacol 18 (1984) 941-946
13. Nawaratne S., Brien J.E., Seeman E., et al. Relationships among liver and kidney volumes, lean body mass and drug clearance. Br J Clin Pharmacol 46 (1998) 447-452
14. Bosma R.J., Krikken J.A., van der Heide J.H., de Jong P.E., and Navis G.J. Obesity and renal hemodynamics. Contrib Nephrol 151 (2006) 184-202
15. Bauer L.A., Black D.J., and Lill J.S. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 54 (1998) 621-625
16. Traynor A.M., Nafziger A.N., and Bertino Jr. J.S. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 39 (1995) 545-548
17. Pai M.P., Norenberg J.P., Anderson T., et al. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother 51 (2007) 2741-2747
18. Roberts J.A., Kruger P., Paterson D.L., and Lipman J. Antibiotic resistance-what's dosing got to do with it?. Crit Care Med 36 (2008) 2433-2440
19. Falagas M.E., and Kopterides P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 64 (2006) 7-15
20. Falagas M.E., and Bliziotis I.A. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?. Int J Antimicrob Agents 29 (2007) 630-636
21. Soriano A., Marco F., Martinez J.A., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46 (2008) 193-200
22. Vollaard E.J., and Clasener H.A. Colonization resistance. Antimicrob Agents Chemother 38 (1994) 409-414
23. Carpenter C.F., and Chambers H.F. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 38 (2004) 994-1000
24. Falagas M.E., and Kasiakou S.K. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40 (2005) 1333-1341
25. Falagas M.E., and Kompoti M. Obesity and infection. Lancet Infect Dis 6 (2006) 438-446
26. Falagas M.E., Athanasoulia A.P., Peppas G., and Karageorgopoulos D.E. Effect of body mass index on the outcome of infections: a systematic review. Obes Rev 10 (2009) 280-289
27. Bartelink I.H., Rademaker C.M., Schobben A.F., and van den Anker J.N. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 45 (2006) 1077-1097
28. Hofmann J., Cetron M.S., Farley M.M., et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 333 (1995) 481-486
29. US Food and Drug Administration. Innovation or stagnation: challenge and opportunity on the critical path to new medical products (March 2004). http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.pdf (accessed July 14, 2008).
30. Bond C.A., and Raehl C.L. 2006 National clinical pharmacy services survey: clinical pharmacy services, collaborative drug management, medication errors, and pharmacy technology. Pharmacotherapy 28 (2008) 1-13